Nanology Labs leverages a patented polymer-lipid platform to create nanoparticles that actively transport therapeutic and diagnostic payloads into cells and across the blood–brain barrier. Its lead product, T-MX (aka Manganescan), accumulates in cancer cells, is MR-detectable, and generates oxygen to reprogram hypoxic tumors from cold to hot, sensitizing them to radiotherapy, chemotherapy, and immunotherapy. T-MX is completing GLP-toxicology and GMP manufacturing in preparation for a Ph1/2 study in patients with oligometastatic brain cancer at Princess Margaret Cancer Center. The company reports extensive safety, efficacy, and manufacturing studies that have de-risked T-MX. Nanology’s platform can deliver proteins, nucleic acids, drugs, and imaging agents, and its work has been published in journals including Journal of the National Cancer Institute, Cancer Research, Advanced Functional Materials, and ACS Nano. The company secured an oversubscribed $3M seed round to advance development. Nanology Labs has developed Manganescan, a low-toxicity MRI contrast agent that uses manganese to improve visualization of early-stage tumours and produces oxygen in tumours to enhance radiation therapy effectiveness. Its platform enables active transport of diagnostic and therapeutic agents to brain tumour tissue. The company is advancing its system toward clinical translation and seeking further investment to reach the next inflection point, per CEO Mohammad Ali Amini. Nanology is a participant in the University of Toronto Early Stage Technology (UTEST) Program, which provides investment capital, mentoring, business strategy, and incubation space. Financially, the company recently received seed funding from FACIT’s Prospects Oncology Fund (amount undisclosed) and previously was one of six recipients of a $50,000 Ontario Brain Institute early-stage award.

Total raised

$3M

Funding rounds

2

Latest round

Seed

Latest activity

May 2021